The Company is engaged in the commercialization of proprietary diagnostic products for breast cancer. Its business strategy is to complete the commercial development of 360 degree, true 3D breast imaging technology for early diagnosis of breast cancer. The Company holds a license under a license agreement to make, have made, use, offer for sale, import, and sell products and services and to practice processes and methods in the field of human diagnostics and therapeutics in the United States and any other countries where approvals are granted or where patent rights may exist in the future with respect to certain licensed patent rights.
‍
izocorp.com
‍
CSE:IZO | OTCQB:IZOZF